Collegium Pharmaceutical (COLL) Stock Analysis & AI Equity Report

Drug Manufacturers - Specialty & Generic USD Explore free reports

Collegium Pharmaceutical (COLL) overview

Collegium Pharmaceutical (COLL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 781m and operating profit of USD 180m; the year-end share price was 46.30 USD and market capitalisation was USD 1,468m. Collegium Pharmaceutical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Collegium Pharmaceutical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 302mFY 2025
Share price46.30 USDFY 2025 year end
RevenueUSD 781mFY 2025
Operating profitUSD 180mFY 2025
Net earningsUSD 62.9mFY 2025
Market capitalisationUSD 1,468mFY 2025 year end

About Collegium Pharmaceutical

Collegium Pharmaceutical commercializes prescription medicines in the United States for attention deficit hyperactivity disorder and moderate to severe pain, along with Symproic. Its products include Jornay PM, a stimulant for ADHD; Belbuca, a buprenorphine buccal film for persistent pain; Xtampza ER, an extended-release oxycodone formulation; and Nucynta immediate- and extended-release tapentadol products for acute or persistent pain.

Generate the Collegium Pharmaceutical report

Collegium Pharmaceutical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Collegium Pharmaceutical and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Collegium Pharmaceutical

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.